Blinded by the Light: The Growing Complexity of p53

Cell

Volumn 137, Issue 3, 2009, Pages 413-431

  Vousden, Karen H ^a   Prives, Carol ^b  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b Howard Hughes Medical Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA; PROTEIN INHIBITOR; PROTEIN P53; PROTEIN P53 ACTIVATOR; PROTEIN P53 INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL AGING; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR STRESS RESPONSE; DNA DAMAGE; GENOMIC INSTABILITY; HUMAN; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW; TRANSCRIPTION REGULATION; TUMOR PROMOTION; TUMOR SUPPRESSOR GENE;

EID: 65349103899     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2009.04.037     Document Type: Review

References (230)

1. Amaravadi R.K., Yu D., Lum J.J., Bui T., Christophorou M.A., Evan G.I., Thomas-Tikhonenko A., and Thompson C.B. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J. Clin. Invest. 117 (2007) 326-336
2. An W., Kim J., and Roeder R.G. Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell 117 (2004) 735-748
3. Appella E., and Anderson C.W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268 (2001) 2764-2772
4. Aranda-Anzaldo A., and Dent M.A. Reassessing the role of p53 in cancer and ageing from an evolutionary perspective. Mech. Ageing Dev. 128 (2007) 293-302
5. Arum O., and Johnson T.E. Reduced expression of the Caenorhabditis elegans p53 ortholog cep-1 results in increased longevity. J. Gerontol. A Biol. Sci. Med. Sci. 62 (2007) 951-959
6. Arva N.C., Gopen T.R., Talbott K.E., Campbell L.E., Chicas A., White D.E., Bond G.L., Levine A.J., and Bargonetti J. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J. Biol. Chem. 280 (2005) 26776-26787
7. Augustyn K.E., Merino E.J., and Barton J.K. A role for DNA-mediated charge transport in regulating p53: Oxidation of the DNA-bound protein from a distance. Proc. Natl. Acad. Sci. USA 104 (2007) 18907-18912
8. Bae B.I., Xu H., Igarashi S., Fujimuro M., Agrawal N., Taya Y., Hayward S.D., Moran T.H., Montell C., Ross C.A., et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47 (2005) 29-41
9. Baptiste-Okoh N., Barsotti A.M., and Prives C. A role for caspase 2 and PIDD in the process of p53-mediated apoptosis. Proc. Natl. Acad. Sci. USA 105 (2008) 1937-1942
10. Baptiste-Okoh N., Barsotti A.M., and Prives C. Caspase 2 is both required for p53-mediated apoptosis and downregulated by p53 in a p21-dependent manner. Cell Cycle 7 (2008) 1133-1138
11. Barboza J.A., Liu G., El-Naggar A.K., and Lozano G. p21 delays tumor onset by preservation of chromosomal stability. Proc. Natl. Acad. Sci. USA 103 (2006) 19842-19847
12. Batta K., and Kundu T.K. Activation of p53 function by human transcriptional coactivator PC4: role of protein-protein interaction, DNA bending, and posttranslational modifications. Mol. Cell. Biol. 27 (2007) 7603-7614
13. Bauer J.H., Poon P.C., Glatt-Deeley H., Abrams J.M., and Helfand S.L. Neuronal expression of p53 dominant-negative proteins in adult Drosophila melanogaster extends life span. Curr. Biol. 15 (2005) 2063-2068
14. Bensaad K., and Vousden K.H. p53: new roles in metabolism. Trends Cell Biol. 17 (2007) 286-291
15. Bensaad K., Tsuruta A., Selak M.A., Vidal M.N., Nakano K., Bartrons R., Gottlieb E., and Vousden K.H. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126 (2006) 107-120
16. Bergamaschi D., Samuels Y., Sullivan A., Zvelebil M., Breyssens H., Bisso A., Del Sal G., Syed N., Smith P., Gasco M., et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat. Genet. 38 (2006) 1133-1141
17. Berns A. Cancer biology: can less be more for p53?. Nature 443 (2006) 153-154
18. Bertheau P., Espie M., Turpin E., Lehmann J., Plassa L.-F., Varna M., Janin A., and de The H. TP53 status and response to chemotherapy in breast cancer. Pathobiology 75 (2008) 132-139
19. Bode A.M., and Dong Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 4 (2004) 793-805
20. Bommer G.T., Gerin I., Feng Y., Kaczorowski A.J., Kuick R., Love R.E., Zhai Y., Giordano T.J., Qin Z.S., Moore B.B., et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 17 (2007) 1298-1307
21. Bonnet S., Archer S.L., Allalunis-Turner J., Haromy A., Beaulieu C., Thompson R., Lee C.T., Lopaschuk G.D., Puttagunta L., Bonnet S., et al. A mitochondrial-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer cell growth. Cancer Cell 11 (2007) 37-51
22. Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A., Xirodimas D.P., Saville M.K., and Lane D.P. p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 19 (2005) 2122-2137
23. Braun C.J., Zhang X., Savelyeva I., Wolff S., Moll U.M., Schepeler T., Orntoft T.F., Andersen C.L., and Dobbelstein M. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res. 68 (2008) 10094-10104
24. Bretaud S., Allen C., Ingham P.W., and Bandmann O. p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson's disease. J. Neurochem. 100 (2007) 1626-1635
25. Brosh R., Shalgi R., Liran A., Landan G., Korotayev K., Nguyen G.H., Enerly E., Johnsen H., Buganim Y., Solomon H., et al. p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol. Syst. Biol 4 (2008) 229
26. CIP1/WAF1 gene in normal diploid human fibroblasts. Science 277 (1997) 831-834
27. Bruins W., Jonker M.J., Bruning O., Pennings J.L., Schaap M.M., Hoogervorst E.M., van Steeg H., Breit T.M., and de Vries A. Delayed expression of apoptotic and cell cycle control genes in carcinogen-exposed bladders of mice lacking p53.S389 phosphorylation. Carcinogenesis 28 (2007) 1814-1823
28. Bruins W., Bruning O., Jonker M.J., Zwart E., van der Hoeven T.V., Pennings J.L., Rauwerda H., de Vries A., and Breit T.M. The absence of Ser389 phosphorylation in p53 affects the basal gene expression level of many p53-dependent genes and alters the biphasic response to UV exposure in mouse embryonic fibroblasts. Mol. Cell. Biol. 28 (2008) 1974-1987
29. Brummelkamp T.R., Fabius A.W., Mullenders J., Madiredjo M., Velds A., Kerkhoven R.M., Bernards R., and Beijersbergen R.L. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat. Chem. Biol. 2 (2006) 202-206
30. Budanov A.V., and Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 134 (2008) 451-460
31. Budhram-Mahadeo V.S., Bowen S., Lee S., Perez-Sanchez C., Ensor E., Morris P.J., and Latchman D.S. Brn-3b enhances the pro-apoptotic effects of p53 but not its induction of cell cycle arrest by cooperating in trans-activation of bax expression. Nucleic Acids Res. 34 (2006) 6640-6652
32. Carvajal D., Tovar C., Yang H., Vu B.T., Heimbrook D.C., and Vassilev L.T. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res. 65 (2005) 1918-1924
33. Cawley S., Bekiranov S., Ng H.H., Kapranov P., Sekinger E.A., Kampa D., Piccolboni A., Sementchenko V., Cheng J., Williams A.J., et al. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 116 (2004) 499-509
34. Cecchinelli B., Porrello A., Lazzari C., Gradi A., Bossi G., D'Angelo M., Sacchi A., and Soddu S. Ser58 of mouse p53 is the homologue of human Ser46 and is phosphorylated by HIPK2 in apoptosis. Cell Death Differ. 13 (2006) 1994-1997
35. Chang T.C., Wentzel E.A., Kent O.A., Ramachandran K., Mullendore M., Lee K.H., Feldmann G., Yamakuchi M., Ferlito M., Lowenstein C.J., et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 26 (2007) 745-752
36. Chao C., Wu Z., Mazur S.J., Borges H., Rossi M., Lin T., Wang J.Y., Anderson C.W., Appella E., and Xu Y. Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol. Cell. Biol. 26 (2006) 6859-6869
37. Chen J., Ruan H., Ng S.M., Gao C., Soo H.M., Wu W., Zhang Z., Wen Z., Lane D.P., and Peng J. Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish. Genes Dev. 19 (2005) 2900-2911
38. Chipuk J.E., Bouchier-Hayes L., Kuwana T., Newmeyer D.D., and Green D.R. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309 (2005) 1732-1735
39. Choudhury A.R., Ju Z., Djojosubroto M.W., Schienke A., Lechel A., Schaetzlein S., Jiang H., Stepczynska A., Wang C., Buer J., et al. Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat. Genet. 39 (2007) 99-105
40. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., Fleming M.D., Schreiber S.L., and Cantley L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumor growth. Nature 452 (2008) 230-233
41. Christophorou M.A., Ringhausen I., Finch A.J., Brown Swigart L., and Evan G.I. The pathological p53-mediated response to DNA damage is distinct from p53-mediated tumor suppression. Nature 14 (2006) 214-217
42. Chuikov S., Kurash J.K., Wilson J.R., Xiao B., Justin N., Ivanov G.S., McKinney K., Tempst P., Prives C., Gamblin S.J., et al. Regulation of p53 activity through lysine methylation. Nature 432 (2004) 353-360
43. Corney D.C., Flesken-Nikitin A., Godwin A.K., Wang W., and Nikitin A.Y. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 67 (2007) 8433-8438
44. Cosme-Blanco W., Shen M.-F., Lazar A.J.F., Pathak S., Lozano G., Multani A.S., and Chang S. Telomere dysfunction suppresses spontaneous tumorigeesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep. 8 (2007) 497-503
45. Crighton D., Wilkinson S., O'Prey J., Syed N., Harrison P.R., Gasco M., Garrone O., Crook T., and Ryan K.M. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 14 (2006) 121-134
46. Cuadrado A., Lafarga V., Cheung P.C., Dolado I., Llanos S., Cohen P., and Nebreda A.R. A new p38 MAP kinase-regulated transcriptional coactivator that stimulates p53-dependent apoptosis. EMBO J. 26 (2007) 2115-2126
47. Culmsee C., and Landshamer S. Molecular insights into mechanisms of the cell death program: role in the progression of neurodegenerative disorders. Curr. Alzheimer Res. 3 (2006) 269-283
48. D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., Gostissa M., Coen S., Marchetti A., Del Sal G., et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 4 (2002) 11-19
49. Das S., Raj L., Zhao B., Kimura Y., Bernstein A., Aaronson S.A., and Lee S.W. Hzf Determines cell survival upon genotoxic stress by modulating p53 transactivation. Cell 130 (2007) 624-637
50. DeBerardinis R.J., Lum J.J., Hatzivassilou G., and Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7 (2008) 11-20
51. Deng Y., Chan S.S., and Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat. Rev. Cancer 8 (2008) 450-458
52. Derry W.B., Putzke A.P., and Rothman J.H. Caenorhabditis elegans p53: role in apoptosis, meiosis and stress resistance. Science 294 (2001) 591-595
53. Di Giovanni S., Knights C.D., Rao M., Yakovlev A., Beers J., Catania J., Avantaggiati M.L., and Faden A.I. The tumor suppressor protein p53 is required for neurite outgrowth and axon regeneration. EMBO J. 25 (2006) 4084-4096
54. Ding K., Lu Y., Nikolovska-Coleska Z., Qiu S., Ding Y., Gao W., Stuckey J., Krajewski K., Roller P.P., Tomita Y., et al. Structure-based design of potent non-peptide MDM2 inhibitors. J. Am. Chem. Soc. 127 (2005) 10130-10131
55. Duan W., Zhu X., Ladenheim B., Yu Q.S., Guo Z., Oyler J., Cutler R.G., Cadet J.L., Greig N.H., and Mattson M.P. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann. Neurol. 52 (2002) 597-606
56. Efeyan A., Garcia-Cao I., Herranz D., Velasco-Miguel S., and Serrano M. Policing of oncogene activity by p53. Nature 443 (2006) 159
57. El-Deiry W.S. Regulation of p53 downstream genes. Semin. Cancer Biol. 8 (1998) 345-357
58. Enari M., Ohmori K., Kitabayashi I., and Taya Y. Requirement of clathrin heavy chain for p53-mediated transcription. Genes Dev. 20 (2006) 1087-1099
59. Enge M., Bao W., Hedstrom E., Jackson S.P., Moumen A., and Selivanova G. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 15 (2009) 171-183
60. Esteve P.O., Chin H.G., and Pradhan S. Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J. Biol. Chem. 282 (2007) 2615-2625
61. Fantin V.R., Syt-Pierre J., and Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, micochondrial physiology, and tumor maintenance. Cancer Cell 9 (2006) 425-434
62. Feng L., Lin T., Uranishi H., Gu W., and Xu Y. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol. Cell. Biol. 25 (2005) 5389-5395
63. Feng Z., Jin S., Zupnick A., Hoh J., de Stanchina E., Lowe S., Prives C., and Levine A.J. p53 tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene 25 (2006) 1-7
64. Feng Z., Hu W., de Stanchina E., Teresky A.K., Jin S., Lowe S., and Levine A.J. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res. 67 (2007) 3043-3053
65. Feng Z., Hu W., Teresky A.K., Hernando E., Cordon-Cardo C., and Levine A.J. Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc. Natl. Acad. Sci. USA 104 (2007) 16633-16638
66. Fogal V., Hsieh J.K., Royer C., Zhong S., and Lu X. Cell cycle-dependent nuclear retention of p53 by E2F1 requires phosphorylation of p53 at Ser315. EMBO J. 24 (2005) 2768-2782
67. Gamper A.M., and Roeder R.G. Multivalent binding of p53 to the STAGA complex mediates coactivator recruitment after UV damage. Mol. Cell. Biol. 28 (2008) 2517-2527
68. Garrison S.P., Jeffers J.R., Yang C., Nilsson J.A., Hall M.A., Rehg J.E., Yue W., Yu J., Zhang L., Onciu M., et al. Selection against PUMA gene expression in Myc-driven B cell lymphomagenesis. Mol. Cell. Biol. 28 (2008) 5391-5402
69. Gatz S.A., and Wiesmuller L. p53 in recombination and repair. Cell Death Differ. 13 (2006) 1003-1016
70. Godar S., Ince T.A., Bell G.W., Feldser D., Donaher J.L., Bergh J., Liu A., Miu K., Watnick R.S., Reinhardt F., et al. Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell 134 (2008) 62-73
71. Gorrini C., Squatrito M., Luise C., Syed N., Perna D., Wark L., Martinato F., Sardella D., Verrecchia A., Bennett S., et al. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature 448 (2007) 1063-1067
72. Gresko E., Roscic A., Ritterhoff S., Vichalkovski A., del Sal G., and Schmitz M.L. Autoregulatory control of the p53 response by caspase-mediated processing of HIPK2. EMBO J. 25 (2006) 1883-1894
73. Gudkov A.V., and Komarova E.A. Prospective therapeutic applications of p53 inhibitors. Biochem. Biophys. Res. Commun. 331 (2005) 726-736
74. Halazonetis T.D., Gorgoulis V.G., and Barteck J. An oncogene-induced DNA damage model for cancer development. Science 319 (2008) 1352-1355
75. Hammond E.M., Mandell D.J., Salim A., Krieg A.J., Johnson T.M., Shirazi H.A., Attardi L.D., and Giaccia A.J. Genome-wide analysis of p53 under hypoxic conditions. Mol. Cell. Biol. 26 (2006) 3492-3504
76. Harms K.L., and Chen X. The functional domains in p53 family proteins exhibit both common and distinct properties. Cell Death Differ. 13 (2006) 890-897
77. He L., He X., Lim L.P., de Stanchina E., Xuan Z., Liang Y., Xue W., Zender L., Magnus J., Ridzon D., et al. A microRNA component of the p53 tumour suppressor network. Nature 447 (2007) 1130-1134
78. Hearnes J.M., Mays D.J., Schavolt K.L., Tang L., Jiang X., and Pietenpol J.A. Chromatin immunoprecipitation-based screen to identify functional genomic binding sites for sequence-specific transactivators. Mol. Cell. Biol. 25 (2005) 10148-10158
79. Hemann M.T., Zilfou J.T., Zhao Z., Burgess D.J., Hannon G.L., and Lowe S.W. Suppression of tumorigenesis by the p53 target PUMA. Proc. Natl. Acad. Sci. USA 101 (2004) 9333-9338
80. Ho W.C., Fitzgerald M.X., and Marmorstein R. Structure of the p53 core domain dimer bound to DNA. J. Biol. Chem. 281 (2006) 20494-20502
81. Hofmann T.G., Moller A., Sirma H., Zentgraf H., Taya Y., Droge W., Will H., and Schmitz M.L. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat. Cell Biol. 4 (2002) 1-10
82. Hoh J., Jin S., Parrado T., Edington J., Levine A.J., and Ott J. The p53MH algorithm and its application in detecting p53-responsive genes. Proc. Natl. Acad. Sci. USA 99 (2002) 8467-8472
83. Homer C., Knight D.A., Hananeia L., Sheard P., Risk J., Lasham A., Royds J.A., and Braithwaite A.W. Y-box factor YB1 controls p53 apoptotic function. Oncogene 24 (2005) 8314-8325
84. Hu W., Feng Z., Teresky A.K., and Levine A.J. p53 regulates maternal reproduction through LIF. Nature 450 (2007) 721-724
85. Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M., Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., and Berger S.L. Repression of p53 activity by Smyd2-mediated methylation. Nature 444 (2006) 629-632
86. Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M., Opravil S., Shiekhattar R., Bedford M.T., Jenuwein T., et al. p53 is regulated by the lysine demethylase LSD1. Nature 449 (2007) 105-108
87. Hudson C.D., Morris P.J., Latchman D.S., and Budhram-Mahadeo V.S. Brn-3a transcription factor blocks p53-mediated activation of proapoptotic target genes Noxa and Bax in vitro and in vivo to determine cell fate. J. Biol. Chem. 280 (2005) 11851-11858
88. Iizuka M., Sarmento O.F., Sekiya T., Scrable H., Allis C.D., and Smith M.M. Hbo1 Links p53-dependent stress signaling to DNA replication licensing. Mol. Cell. Biol. 28 (2008) 140-153
89. Imbriano C., Gurtner A., Cocchiarella F., Di Agostino S., Basile V., Gostissa M., Dobbelstein M., Del Sal G., Piaggio G., and Mantovani R. Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters. Mol. Cell. Biol. 25 (2005) 3737-3751
90. Innocente S.A., and Lee J.M. p53 is a NF-Y- and p21-independent, Sp1-dependent repressor of cyclin B1 transcription. FEBS Lett. 579 (2005) 1001-1007
91. Itahana K., Mao H., Jin A., Itahana Y., Clegg H.V., Lindstrom M.S., Bhat K.P., Godfrey V.L., Evan G.I., and Zhang Y. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 12 (2007) 355-366
92. Ito A., Lai C.H., Zhao X., Saito S., Hamilton M.H., Appella E., and Yao T.P. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 20 (2001) 1331-1340
93. Ito A., Kawaguchi Y., Lai C.H., Kovacs J.J., Higashimoto Y., Appella E., and Yao T.P. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 21 (2002) 6236-6245
94. Ivanov G.S., Ivanova T., Kurash J., Ivanov A., Chuikov S., Gizatullin F., Herrera-Medina E.M., Rauscher III F., Reinberg D., and Barlev N.A. Methylation-acetylation interplay activates p53 in response to DNA damage. Mol. Cell. Biol. 27 (2007) 6756-6769
95. Iyer N.G., Chin S.F., Ozdag H., Daigo Y., Hu D.E., Cariati M., Brindle K., Aparicio S., and Caldas C. p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proc. Natl. Acad. Sci. USA 101 (2004) 7386-7391
96. Janicke R.U., Sohn D., and Schulze-Osthoff K. The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ. 15 (2008) 959-976
97. Jansson M., Durant S.T., Cho E.C., Sheahan S., Edelmann M., Kessler B., and La Thangue N.B. Arginine methylation regulates the p53 response. Nat. Cell Biol. 10 (2008) 1431-1439
98. Jin Y., Zeng S.X., Lee H., and Lu H. MDM2 mediates p300/CREB-binding protein-associated factor ubiquitination and degradation. J. Biol. Chem. 279 (2004) 20035-20043
99. Johnson R.A., Ince T.A., and Scotto K.W. Transcriptional repression by p53 through direct binding to a novel DNA element. J. Biol. Chem. 276 (2001) 27716-27720
100. Johnson T.M., Hammond E.M., Giaccia A., and Attardi L.D. The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. Nat. Genet. 37 (2005) 145-152
101. Jones N.C., Lynn M.L., Gaudenz K., Sakai D., Aoto K., Rey J.P., Glynn E.F., Ellington L., Du C., Dixon J., et al. Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function. Nat. Med. 14 (2008) 125-133
102. Jones R.G., and Thompson C.B. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 23 (2009) 537-548
103. Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., and Thompson C.B. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 18 (2005) 283-293
104. Jordan J.J., Menendez D., Inga A., Nourredine M., Bell D., and Resnick M.A. Noncanonical DNA motifs as transactivation targets by wild type and mutant p53. PLoS Genet. 4 (2008) e1000104
105. Jung E.J., Liu G., Zhou W., and Chen X. Myosin VI is a mediator of the p53-dependent cell survival pathway. Mol. Cell. Biol. 26 (2006) 2175-2186
106. Kawauchi K., Araki K., Tobiume K., and Tanaka N. p53 regulates glucose metabolism though an IKK-NF-kB pathway and inhibits cell transformation. Nat. Cell Biol. 10 (2008) 611-618
107. Kay C., Jeyendran R.S., and Coulam C.B. p53 tumour suppressor gene polymorphism is associated with recurrent implantation failure. Reprod. Biomed. Online 13 (2006) 492-496
108. Kitagawa M., Lee S.H., and McCormick F. Skp2 suppresses p53-dependent apoptosis by inhibiting p300. Mol. Cell 29 (2008) 217-231
109. Kitayner M., Rozenberg H., Kessler N., Rabinovich D., Shaulov L., Haran T.E., and Shakked Z. Structural basis of DNA recognition by p53 tetramers. Mol. Cell 22 (2006) 741-753
110. Knights C.D., Catania J., Di Giovanni S., Muratoglu S., Perez R., Swartzbeck A., Quong A.A., Zhang X., Beerman T., Pestell R.G., et al. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J. Cell Biol. 173 (2006) 533-544
111. Kobet E., Zeng X., Zhu Y., Keller D., and Lu H. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc. Natl. Acad. Sci. USA 97 (2000) 12547-12552
112. Kondoh H., Lleonart M.E., Gil J., Wng J., Degan P., Peters G., Martinez D., Carnero A., and Beach D. Glycolytic enzymes can modulate cellular lifespan. Cancer Res. 65 (2005) 177-185
113. Kortlever R.M., Higgins P.J., and Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat. Cell Biol. 8 (2006) 877-884
114. Kranz D., and Dobbelstein M. Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy. Cancer Res. 66 (2006) 10274-10280
115. Krummel K.A., Lee C.J., Toledo F., and Wahl G.M. The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc. Natl. Acad. Sci. USA 102 (2005) 10188-10193
116. Kruse J.P., and Gu W. SnapShot: p53 posttranslational modifications. Cell 133 (2008) 930
117. Kumamoto K., Spillare E.A., Fujita K., Horikawa I., Yamashita T., Appella E., Nagashima M., Takenoshita S., Yokota J., and Harris C.C. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res. 68 (2008) 3193-3203
118. Lain S., Hollick J.J., Campbell J., Staples O.D., Higgins M., Aoubala M., McCarthy A., Appleyard V., Murray K.E., Baker L., et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13 (2008) 454-463
119. Lanni C., Uberti D., Racchi M., Govoni S., and Memo M. Unfolded p53: a potential biomarker for Alzheimer's disease. J. Alzheimers Dis. 12 (2007) 93-99
120. Laptenko O., and Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ. 13 (2006) 951-961
121. Le Cam L., Linares L.K., Paul C., Julien E., Lacroix M., Hatchi E., Triboulet R., Bossis G., Shmueli A., Rodriguez M.S., et al. E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell 127 (2006) 775-788
122. Leal J.F., Fominaya J., Cascon A., Guijarro M.V., Blanco-Aparicio C., Lleonart M., Castro M.E., Ramon Y., Cajal S., Robledo M., et al. Cellular senescence bypass screen identifies new putative tumor suppressor genes. Oncogene 27 (2008) 1961-1970
123. Leker R.R., Aharonowiz M., Greig N.H., and Ovadia H. The role of p53-induced apoptosis in cerebral ischemia: effects of the p53 inhibitor pifithrin alpha. Exp. Neurol. 187 (2004) 478-486
124. Lin T., Chao C., Saito S., Mazur S.J., Murphy M.E., Appella E., and Xu Y. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat. Cell Biol. 7 (2005) 165-171
125. Linares L.K., Kiernan R., Triboulet R., Chable-Bessia C., Latreille D., Cuvier O., Lacroix M., Le Cam L., Coux O., and Benkirane M. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat. Cell Biol. 9 (2007) 331-338
126. Liu G., Parant J.M., Lang G., Chau P., Chavez-Reyes A., El-Naggar A.K., Multani A., Chang S., and Lozano G. Chromosomal stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat. Genet. 36 (2004) 63-68
127. Liu P., Xu B., Cavalieri T.A., and Hock C.E. Pifithrin-alpha attenuates p53-mediated apoptosis and improves cardiac function in response to myocardial ischemia/reperfusion in aged rats. Shock 26 (2006) 608-614
128. Liu B., Chen Y., and St Clair D.K. ROS and p53: a verstile partnership. Free Radic. Biol. Med. 44 (2008) 1529-1535
129. Liu Y., Elf S.E., Miyata Y., Sashida G., Liu Y., Huang G., Di Giandomenico S., Lee J.M., Deblasio A., Menendez S., et al. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 4 (2009) 37-48
130. Lohr K., Moritz C., Contente A., and Dobbelstein M. p21/CDKN1A mediates negative regulation of transcription by p53. J. Biol. Chem. 278 (2003) 32507-32516
131. Ma W., Sung H.J., Park J.Y., Matoba S., and Hwang P.M. A pivotal role for p53: balancing aerobic respiration and glycolysis. J. Bioenerg. Biomembr. 39 (2007) 243-246
132. Mantovani F., Tocco F., Girardini J., Smith P., Gasco M., Lu X., Crook T., and Del Sal G. The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat. Struct. Mol. Biol. 14 (2007) 912-920
133. Marine J.C., Francoz S., Maetens M., Wahl G., Toledo F., and Lozano G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ. 13 (2006) 927-934
134. Marine J.C., Dyer M.A., and Jochemsen A.G. MDMX: from bench to bedside. J. Cell Sci. 120 (2007) 371-378
135. Martins C.P., Brown-Swigart L., and Evan G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127 (2006) 1323-1334
136. Matheu A., Maraver A., Klatt P., Flores I., Garcia-Cao I., Borras C., Flores J.M., Vina J., Blasco M.A., and Serrano M. Delayed ageing through damage protection by the Arf/p53 pathway. Nature 448 (2007) 375-379
137. Matheu A., Maraver A., and Serrano M. The Arf/p53 pathway in cancer and aging. Cancer Res. 68 (2008) 6031-6034
138. Matoba S., Kang J.G., Patino W.D., Wragg A., Boehm M., Gavrilova O., Hurley P.J., Bunz F., and Hwang P.M. p53 regulates mitochondrial respiration. Science 312 (2006) 1650-1653
139. Matsui T., Katsuno Y., Inoue T., Fujita F., Joh T., Niida H., Murakami H., Itoh M., and Nakanishi M. Negative regulation of Chk2 expression by p53 is dependent on the CCAAT-binding transcription factor NF-Y. J. Biol. Chem. 279 (2004) 25093-25100
140. Matthew R., Karantza-Wadsworth V., and White E. Role of autophagy in cancer. Nat. Rev. Cancer 7 (2007) 961-967
141. McKinney K., Mattia M., Gottifredi V., and Prives C. p53 linear diffusion along DNA requires its C terminus. Mol. Cell 16 (2004) 413-424
142. McLure K.G., Takagi M., and Kastan M.B. NAD+ modulates p53 DNA binding specificity and function. Mol. Cell. Biol. 24 (2004) 9958-9967
143. Meletis K., Wirta V., Hede S.M., Nister M., Lundeberg J., and Frisen J. p53 suppresses the self-renewal of adult neural stem cells. Development 133 (2006) 363-369
144. Michalak E.M., Villunger A., Adams J.M., and Strasser A. In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ. 15 (2008) 1019-1029
145. Miled C., Pontoglio M., Garbay S., Yaniv M., and Weitzman J.B. A genomic map of p53 binding sites identifies novel p53 targets involved in an apoptotic network. Cancer Res. 65 (2005) 5096-5104
146. Minsky N., and Oren M. The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. Mol. Cell 16 (2004) 631-639
147. Moll U.M., Wolff S., Speidel D., and Deppert W. Transcription-independent pro-apoptotic functions of p53. Curr. Opin. Cell Biol. 17 (2005) 631-636
148. Montanaro L., Trere D., and Derenzini M. Nucleolus, ribosomes, and cancer. Am. J. Pathol. 173 (2008) 301-310
149. Morselli E., Tasdemir E., Maiuri M.C., Galluzzi L., Kepp O., Criollo A., Vicencio J.M., Soussi T., and Kroemer G. Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle 7 (2008) 3056-3061
150. Moumen A., Masterson P., O'Connor M.J., and Jackson S.P. hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Cell 123 (2005) 1065-1078
151. Ohkubo S., Tanaka T., Taya Y., Kitazato K., and Prives C. Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription. J. Biol. Chem. 281 (2006) 16943-16950
152. Okoshi R., Ozaki T., Yamamoto H., Ando K., Koida N., Ono S., Koda T., Kamijo T., Nakagawara A., and Kizaki H. Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J. Biol. Chem. 283 (2008) 3979-3987
153. Olsson A., Manzl C., Strasser A., and Villunger A. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression?. Cell Death Differ. 14 (2007) 1561-1575
154. Ou Y.H., Chung P.H., Sun T.P., and Shieh S.Y. p53 C-terminal phosphorylation by CHK1 and CHK2 participates in the regulation of DNA-damage-induced C-terminal acetylation. Mol. Biol. Cell 16 (2005) 1684-1695
155. Pan Y., and Nussinov R. p53-Induced DNA bending: the interplay between p53-DNA and p53-p53 interactions. J. Phys. Chem. B 112 (2008) 6716-6724
156. Paris R., Henry R.E., Stephens S.J., McBryde M., and Espinosa J.M. Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation. Cell Cycle 7 (2008) 2427-2433
157. Perfettini J.L., Castedo M., Nardacci R., Ciccosanti F., Boya P., Roumier T., Larochette N., Piacentini M., and Kroemer G. Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope. J. Exp. Med. 201 (2005) 279-289
158. Petitjean A., Achatz M.I., Borresen-Dale A.L., Hainaut P., and Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26 (2007) 2157-2165
159. Piccolo S. p53 regulation orchestrates the TGF-beta response. Cell 133 (2008) 767-769
160. Pietsch E.C., Humbey O., and Murphy M.E. Polymorphisms in the p53 pathway. Oncogene 25 (2006) 1602-1611
161. Poyurovsky M.V., and Prives C. Unleashing the power of p53: lessons from mice and men. Genes Dev. 20 (2006) 125-131
162. Qu L., Huang S., Baltzis D., Rivas-Estilla A.M., Pluquet O., Hatzoglou M., Koumenis C., Taya Y., Yoshimura A., and Koromilas A.E. Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta. Genes Dev. 18 (2004) 261-277
163. Raver-Shapira N., Marciano E., Meiri E., Spector Y., Rosenfeld N., Moskovits N., Bentwich Z., and Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell 26 (2007) 731-743
164. Riley T., Sontag E., Chen P., and Levine A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 9 (2008) 402-412
165. Rinaldo C., Prodosmo A., Mancini F., Iacovelli S., Sacchi A., Moretti F., and Soddu S. MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. Mol. Cell 25 (2007) 739-750
166. Ringshausen I., O'Shea C.C., Finch A.J., Swigart L.B., and Evan G.I. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10 (2006) 501-514
167. Rother K., Li Y.Y., Tschop K., Kirschner R., Muller G.A., Mossner J., and Engeland K. Expression of cyclin-dependent kinase subunit 1 (Cks1) is regulated during the cell cycle by a CDE/CHR tandem element and is
168. Rowan S., Ludwig R.L., Haupt Y., Bates S., Lu X., Oren M., and Vousden K.H. Specific loss of apoptotic but not cell cycle arrest function in a human tumour derived p53 mutant. EMBO J. 15 (1996) 827-838
169. Rui Y., Xu Z., Lin S., Li Q., Rui H., Luo W., Zhou H.M., Cheung P.Y., Wu Z., Ye Z., et al. Axin stimulates p53 functions by activation of HIPK2 kinase through multimeric complex formation. EMBO J. 23 (2004) 4583-4594
170. Sablina A.A., Budanov A.V., Ilyinskaya G.V., Agapova L.S., Kravchenko J.E., and Chumakov P.M. The antioxidant function of the p53 tumor suppressor gene. Nat. Med. 11 (2005) 1306-1313
171. Sachdeva M., Zhu S., Wu F., Wu H., Walia V., Kumar S., Elble R., Watabe K., and Mo Y.Y. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc. Natl. Acad. Sci. USA 106 (2009) 3207-3212
172. Sbisa E., Catalano D., Grillo G., Licciulli F., Turi A., Liuni S., Pesole G., De Grassi A., Caratozzolo M.F., D'Erchia A.M., et al. p53FamTaG: a database resource of human p53, p63 and p73 direct target genes combining in silico prediction and microarray data. BMC Bioinformatics 8 Suppl 1 (2007) S20
173. Schuler M., and Green D.R. Transcription, apoptosis and p53: catch-22. Trends Genet. 21 (2005) 182-187
174. Schumm K., Rocha S., Caamano J., and Perkins N.D. Regulation of p53 tumour suppressor target gene expression by the p52 NF-kappaB subunit. EMBO J. 25 (2006) 4820-4832
175. Selivanova G., and Wiman K.G. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 26 (2007) 2243-2254
176. Sengupta S., Shimamoto A., Koshiji M., Pedeux R., Rusin M., Spillare E.A., Shen J.C., Huang L.E., Lindor N.M., Furuichi Y., et al. Tumor suppressor p53 represses transcription of RECQ4 helicase. Oncogene 24 (2005) 1738-1748
177. Senzer N., and Nemunaitis J. A review of contusugene ladenovec (Advexin) p53 therapy. Curr. Opin. Mol. Ther. 11 (2009) 54-61
178. Shangary S., and Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu. Rev. Pharmacol. Toxicol. 49 (2009) 223-241
179. Shats I., Milyavsky M., Tang X., Stambolsky P., Erez N., Brosh R., Kogan I., Braunstein I., Tzukerman M., Ginsberg D., et al. p53-dependent down-regulation of telomerase is mediated by p21waf1. J. Biol. Chem. 279 (2004) 50976-50985
180. Shi X., Kachirskaia I., Yamaguchi H., West L.E., Wen H., Wang E.W., Dutta S., Appella E., and Gozani O. Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol. Cell 27 (2007) 636-646
181. Shmueli A., and Oren M. Mdm2: p53's lifesaver?. Mol. Cell 25 (2007) 794-796
182. Smeenk L., van Heeringen S.J., Koeppel M., van Driel M.A., Bartels S.J., Akkers R.C., Denissov S., Stunnenberg H.G., and Lohrum M. Characterization of genome-wide p53-binding sites upon stress response. Nucleic Acids Res. 36 (2008) 3639-3654
183. St Clair S., Giono L., Varmeh-Ziaie S., Resnick-Silverman L., Liu W.J., Padi A., Dastidar J., DaCosta A., Mattia M., and Manfredi J.J. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Mol. Cell 16 (2004) 725-736
184. Strom E., Sathe S., Komarov P.G., Chernova O.B., Pavlovska I., Shyshynova I., Bosykh D.A., Burdelya L.G., Macklis R.M., Skaliter R., et al. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat. Chem. Biol. 2 (2006) 474-479
185. Sullivan A., and Lu X. ASPP: a new family of oncogenes and tumour suppressor genes. Br. J. Cancer 96 (2007) 196-200
186. Sur S., Pagliarini R., Bunz F., Rago C., Diaz Jr. L.A., Kinzler K.W., Vogelstein B., and Papadopoulos N. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc. Natl. Acad. Sci. USA 106 (2009) 3964-3969
187. Sutcliffe J.E., and Brehm A. Of flies and men; p53, a tumour suppressor. FEBS Lett. 567 (2004) 86-91
188. Sykes S.M., Mellert H.S., Holbert M.A., Li K., Marmorstein R., Lane W.S., and McMahon S.B. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol. Cell 24 (2006) 841-851
189. Tafvizi A., Huang F., Leith J.S., Fersht A.R., Mirny L.A., and van Oijen A.M. Tumor suppressor p53 slides on DNA with low friction and high stability. Biophys. J. 95 (2008) L01-L03
190. Taira N., Nihira K., Yamaguchi T., Miki Y., and Yoshida K. DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol. Cell 25 (2007) 725-738
191. Tanaka T., Ohkubo S., Tatsuno I., and Prives C. hCAS/CSE1L associates with chromatin and regulates expression of select p53 target genes. Cell 130 (2007) 638-650
192. Tang X., Milyavsky M., Shats I., Erez N., Goldfinger N., and Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 23 (2004) 5759-5769
193. Tang Y., Luo J., Zhang W., and Gu W. Tip60-dependent acetylation of p53 modulates the decision between cell cycle arrest and apoptosis. Mol. Cell 24 (2006) 827-839
194. Tang Y., Zhao W., Chen Y., Zhao Y., and Gu W. Acetylation is indispensable for p53 activation. Cell 133 (2008) 612-626
195. Tarasov V., Jung P., Verdoodt B., Lodygin D., Epanchintsev A., Menssen A., Meister G., and Hermeking H. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6 (2007) 1586-1593
196. Tasdemir E., Maiuri M.C., Galluzzi L., Vitale I., Djavaheri-Mergny M., D'Amelio M., Criollo A., Morselli E., Zhu C., Harper F., et al. Regulation of autophagy by cytoplasmic p53. Nat. Cell Biol. 10 (2008) 676-687
197. Tazawa H., Tsuchiya N., Izumiya M., and Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc. Natl. Acad. Sci. USA 104 (2007) 15472-15477
198. Teodoro J.G., Evans S.K., and Green M.R. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J. Mol. Med. 85 (2007) 1175-1186
199. Teufel D.P., Freund S.M., Bycroft M., and Fersht A.R. Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53. Proc. Natl. Acad. Sci. USA 104 (2007) 7009-7014
200. Tidow H., Melero R., Mylonas E., Freund S.M., Grossmann J.G., Carazo J.M., Svergun D.I., Valle M., and Fersht A.R. Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex. Proc. Natl. Acad. Sci. USA 104 (2007) 12324-12329
201. Toledo F., and Wahl G.M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6 (2006) 909-923
202. Toledo F., Krummel K.A., Lee C.J., Liu C.W., Rodewald L.W., Tang M., and Wahl G.M. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 9 (2006) 273-285
203. Van Nguyen T., Puebla-Osorio N., Pang H., Dujka M.E., and Zhu C. DNA damage-induced cellular senescence is sufficient to suppress tumorigenesis: a mouse model. J. Exp. Med. 204 (2007) 1453-1461
204. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (2004) 844-848
205. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., and Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 445 (2007) 661-665
206. Vousden K.H., and Lane D.P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8 (2007) 275-283
207. Wang C., Ivanov A., Chen L., Fredericks W.J., Seto E., Rauscher III F.J., and Chen J. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation. EMBO J. 24 (2005) 3279-3290
208. Wang P., Yu J., and Zhang L. The nuclear function of p53 is required for PUMA-mediated apoptosis induced by DNA damage. Proc. Natl. Acad. Sci. USA 104 (2007) 4054-4059
209. Wang Y.V., Wade M., Wong E., Li Y.C., Rodewald L.W., and Wahl G.M. Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation. Proc. Natl. Acad. Sci. USA 104 (2007) 12365-12370
210. Weber A., Marquardt J., Elzi D., Forster N., Starke S., Glaum A., Yamada D., Defossez P.A., Delrow J., Eisenman R.N., et al. Zbtb4 represses transcription of P21CIP1 and controls the cellular response to p53 activation. EMBO J. 27 (2008) 1563-1574
211. Wei C.L., Wu Q., Vega V.B., Chiu K.P., Ng P., Zhang T., Shahab A., Yong H.C., Fu Y., Weng Z., et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 124 (2006) 207-219
212. Wei G., Li A.G., and Liu X. Insights into selective activation of p53 DNA binding by c-Abl. J. Biol. Chem. 280 (2005) 12271-12278
213. Wei X., Xu H., and Kufe D. Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell 7 (2005) 167-178
214. White D.E., Talbott K.E., Arva N.C., and Bargonetti J. Mouse double minute 2 associates with chromatin in the presence of p53 and is released to facilitate activation of transcription. Cancer Res. 66 (2006) 3463-3470
215. Wilkinson D.S., Tsai W.W., Schumacher M.A., and Barton M.C. Chromatin-bound p53 anchors activated Smads and the mSin3A corepressor to confer transforming-growth-factor-beta-mediated transcription repression. Mol. Cell. Biol. 28 (2008) 1988-1998
216. Wu W.S., Heinrichs S., Xu D., Garrison S.P., Zambetti G.P., Adams J.M., and Look A.T. Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell 123 (2005) 641-653
217. Xenaki G., Ontikatze T., Rajendran R., Stratford I.J., Dive C., Krstic-Demonacos M., and Demonacos C. PCAF is an HIF-1alpha cofactor that regulates p53 transcriptional activity in hypoxia. Oncogene 27 (2008) 5785-5796
218. Xu Y., Zhang J., and Chen X. The activity of p53 is differentially regulated by Brm- and Brg1-containing SWI/SNF chromatin remodeling complexes. J. Biol. Chem. 282 (2007) 37429-37435
219. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., Cordon-Cardo C., and Lowe S.W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445 (2007) 656-660
220. Yamakuchi M., Ferlito M., and Lowenstein C.J. miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. USA 105 (2008) 13421-13426
221. Yoshida K., Liu H., and Miki Y. Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage. J. Biol. Chem. 281 (2006) 5734-5740
222. Yu J., and Zhang L. No PUMA, no death: implications for p53-dependent apoptosis. Cancer Cell 4 (2003) 248-249
223. Zaky A., Busso C., Izumi T., Chattopadhyay R., Bassiouny A., Mitra S., and Bhakat K.K. Regulation of the human AP-endonuclease (APE1/Ref-1) expression by the tumor suppressor p53 in response to DNA damage. Nucleic Acids Res. 36 (2008) 1555-1566
224. Zhan M., Yu D., Liu J., Glazer R.I., Hannay J., and Pollock R.E. Transcriptional repression of protein kinase Calpha via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation. J. Biol. Chem. 280 (2005) 4825-4833
225. Zhang X., Krutchinsky A., Fukuda A., Chen W., Yamamura S., Chait B.T., and Roeder R.G. MED1/TRAP220 exists predominantly in a TRAP/ Mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription. Mol. Cell 19 (2005) 89-100
226. Zhao B.X., Chen H.Z., Lei N.Z., Li G.D., Zhao W.X., Zhan Y.Y., Liu B., Lin S.C., and Wu Q. EMBO J. 25 (2006) 5703-5715
227. Zhou Y., Zhong Y., Wang Y., Zhang X., Batista D.L., Gejman R., Ansell P.J., Zhao J., Weng C., and Klibanski A. Activation of p53 by MEG3 non-coding RNA. J. Biol. Chem. 282 (2007) 24731-24742
228. Zhu N., Gu L., Findley H.W., Chen C., Dong J.T., Yang L., and Zhou M. KLF5 Interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J. Biol. Chem. 281 (2006) 14711-14718
229. Zhu Q., Wani G., Yao J., Patnaik S., Wang Q.E., El-Mahdy M.A., Praetorius-Ibba M., and Wani A.A. The ubiquitin-proteasome system regulates p53-mediated transcription at p21waf1 promoter. Oncogene 26 (2007) 4199-4208
230. Zupnick A., and Prives C. Mutational analysis of the p53 core domain L1 loop. J. Biol. Chem. 281 (2006) 20464-20473